X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6380) 6380
Publication (437) 437
Book Review (111) 111
Book Chapter (86) 86
Newspaper Article (30) 30
Magazine Article (13) 13
Book / eBook (12) 12
Conference Proceeding (9) 9
Government Document (8) 8
Newsletter (7) 7
Paper (4) 4
Trade Publication Article (3) 3
Streaming Video (2) 2
Data Set (1) 1
Dissertation (1) 1
Presentation (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5543) 5543
index medicus (3428) 3428
female (3059) 3059
male (2874) 2874
secondary prevention (2277) 2277
middle aged (2197) 2197
adult (2042) 2042
aged (1586) 1586
treatment outcome (1456) 1456
risk factors (1009) 1009
oncology (1005) 1005
prevention (921) 921
medicine & public health (796) 796
adolescent (795) 795
surgery (784) 784
retrospective studies (738) 738
prophylaxis (713) 713
care and treatment (699) 699
cancer (680) 680
hematology (638) 638
child (599) 599
follow-up studies (599) 599
health aspects (573) 573
recurrence (567) 567
aged, 80 and over (545) 545
therapy (540) 540
chemotherapy (524) 524
secondary prophylaxis (508) 508
analysis (500) 500
medicine, general & internal (500) 500
young adult (478) 478
drug therapy (476) 476
clinical neurology (474) 474
research (468) 468
gastroenterology & hepatology (461) 461
prognosis (455) 455
immunology (449) 449
risk (449) 449
time factors (440) 440
prospective studies (435) 435
animals (420) 420
management (415) 415
transplantation (406) 406
children (402) 402
child, preschool (396) 396
pharmacology & pharmacy (387) 387
metastasis (381) 381
infectious diseases (377) 377
mortality (374) 374
double-blind (355) 355
diagnosis (344) 344
patients (322) 322
antineoplastic combined chemotherapy protocols - therapeutic use (319) 319
pediatrics (306) 306
risk-factors (303) 303
infant (297) 297
abridged index medicus (291) 291
survival (291) 291
survival rate (291) 291
combined modality therapy (290) 290
secondary prevention - methods (280) 280
drug therapy, combination (279) 279
clinical trials (276) 276
neurosciences (270) 270
randomized controlled trials as topic (268) 268
trial (268) 268
drug administration schedule (266) 266
internal medicine (266) 266
incidence (255) 255
liver neoplasms - secondary (255) 255
brain neoplasms - secondary (252) 252
disease (252) 252
infections (249) 249
secondary (249) 249
cardiac & cardiovascular systems (245) 245
medicine (242) 242
peripheral vascular disease (242) 242
immunization, secondary (241) 241
anticoagulants - therapeutic use (237) 237
psychiatry (234) 234
relapse (234) 234
aspirin (230) 230
risk assessment (230) 230
efficacy (229) 229
medical research (229) 229
infection (224) 224
survival analysis (223) 223
hematology, oncology and palliative medicine (211) 211
stroke (211) 211
usage (207) 207
pregnancy (205) 205
liver transplantation (195) 195
dosage and administration (192) 192
epidemiology (189) 189
bone neoplasms - secondary (188) 188
complications (188) 188
diseases (188) 188
randomized-trial (188) 188
anti-bacterial agents - therapeutic use (187) 187
studies (187) 187
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6127) 6127
German (163) 163
Russian (66) 66
French (65) 65
Spanish (41) 41
Japanese (25) 25
Polish (16) 16
Italian (13) 13
Chinese (8) 8
Dutch (5) 5
Hungarian (4) 4
Portuguese (4) 4
Turkish (4) 4
Bulgarian (3) 3
Czech (3) 3
Swedish (3) 3
Ukrainian (3) 3
Danish (2) 2
Slovak (2) 2
Croatian (1) 1
Finnish (1) 1
Korean (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 25, pp. 2367 - 2376
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2009, Volume 361, Issue 18, pp. 1748 - 1759
Journal Article
Cancer, ISSN 0008-543X, 09/2010, Volume 116, Issue 18, pp. 4283 - 4290
BACKGROUND: The outcome of patients with systemic diffuse large B‐cell lymphoma (DLBCL) had improved over the past decade with the addition of monoclonal... 
methotrexate | central nervous system prophylaxis | diffuse large B‐cell lymphoma | central nervous system lymphoma | Central nervous system prophylaxis | Methotrexate | Central nervous system lymphoma | Diffuse large B-cell lymphoma | INVOLVEMENT | INTERMEDIATE-GRADE | diffuse large B-cell lymphoma | INTRATHECAL CHEMOTHERAPY | STUDY-GROUP DSHNHL | RELAPSE | ONCOLOGY | RITUXIMAB | NON-HODGKINS-LYMPHOMA | CHOP | AGGRESSIVE LYMPHOMA | ELDERLY-PATIENTS | Doxorubicin - therapeutic use | Recurrence | Injections, Intravenous | Humans | Middle Aged | Male | Risk | Vincristine - analysis | Antineoplastic Combined Chemotherapy Protocols - analysis | Cyclophosphamide - therapeutic use | Central Nervous System Neoplasms - secondary | Central Nervous System Neoplasms - prevention & control | Cyclophosphamide - analysis | Adult | Female | Prednisone - analysis | Antibodies, Monoclonal, Murine-Derived | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Rituximab | Doxorubicin - analysis | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Methotrexate - adverse effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Methotrexate - administration & dosage | Aged | Central Nervous System Neoplasms - drug therapy | Prednisone - therapeutic use | Prevention | Care and treatment | Relapse | Demographic aspects | Nervous system cancer | Dosage and administration | Non-Hodgkin's lymphomas | Research | Cancer | complications | Mortality | Central nervous system | lymphoma | survival | renal function | chemotherapy | Risk factors | Intravenous administration | Renal function | Risk groups | Prophylaxis | Prednisone | Doxorubicin | Survival | Vincristine | Chemotherapy | Cyclophosphamide | Monoclonal antibodies | rituximab | B-cell lymphoma
Journal Article
The Lancet, ISSN 0140-6736, 09/2003, Volume 362, Issue 9386, pp. 789 - 797
Despite important advances in treatment, the risk of recurrent ischaemic events is high both early and late after an acute coronary syndrome. We aimed to... 
ACTIVE FORM | MEDICINE, GENERAL & INTERNAL | DIRECT THROMBIN INHIBITOR | MANAGEMENT | PHARMACOKINETICS | NO INFLUENCE | MELAGATRAN | PREVENTION | ACUTE CORONARY SYNDROMES | UNSTABLE ANGINA | PHARMACODYNAMICS | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Myocardial Ischemia - prevention & control | Male | Treatment Outcome | Secondary Prevention | Myocardial Infarction - drug therapy | Azetidines - therapeutic use | Benzylamines | Placebos | Female | Aged | Aspirin - therapeutic use | Myocardial Infarction - prevention & control | Prodrugs - therapeutic use | Drug Therapy, Combination | Evaluation | Care and treatment | Heart attack | Cardiovascular agents | Heart attacks | Drug therapy | Disease control | Medical treatment | Clinical outcomes | Myocardial infarction | Anticoagulants | Enzymes | Stroke | Control methods | Mortality | Prophylaxis | Thrombin | Acetylsalicylic acid | Patients | Evidence-based medicine | Investigations | Bleeding | Randomization | Motivation | Acids | Ischemia | Infarction | Acute coronary syndromes | Health risk assessment | Drug dosages | Comparative Study | Recurrence/prevention & control | Aspirin/therapeutic use | Administration; Oral | Myocardial Ischemia/prevention & control | Drug Therapy; Combination | Research Support; Non-U.S. Gov't | Azetidines/therapeutic use | Myocardial Infarction/drug therapy/prevention & control | Prodrugs/therapeutic use
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2013, Volume 11, Issue 1, pp. 56 - 70
Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been... 
Clinical practice guidelines | Anticoagulant | GRADE system | Bleeding | Venous thromboembolism | Cancer | DEEP-VEIN THROMBOSIS | SECONDARY PREVENTION | PERIOPERATIVE THROMBOPROPHYLAXIS | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | PERIPHERAL VASCULAR DISEASE | COMPRESSION STOCKINGS | PLACEBO-CONTROLLED TRIAL | HEMATOLOGY | LONG-TERM TREATMENT | VENA-CAVA FILTERS | UNFRACTIONATED HEPARIN | Recurrence | Humans | Antineoplastic Agents - therapeutic use | Venous Thromboembolism - drug therapy | Patient Selection | Fibrinolytic Agents - adverse effects | Neoplasms - complications | Venous Thromboembolism - prevention & control | Neoplasms - blood | Time Factors | Fibrinolytic Agents - therapeutic use | Venous Thromboembolism - diagnosis | Risk Assessment | Risk Factors | Cooperative Behavior | Benchmarking | Treatment Outcome | International Cooperation | Evidence-Based Medicine | Consensus | Vena Cava Filters | Neoplasms - drug therapy | Venous Thromboembolism - etiology | Thrombolytic Therapy | Hemorrhage - chemically induced | Medical colleges | Aspirin | Glycosaminoglycans | Brain tumors | Leukemia | Oncology, Experimental | Practice guidelines (Medicine) | Laparoscopic surgery | Anticoagulants (Medicine) | Laparoscopy | Transplantation | Metastasis | Research | Pulmonary embolism | Blood circulation disorders | Cancer patients | Chemotherapy | Bone marrow | Adults | Drug therapy | Health aspects | Public health | Clinical medicine | Patients
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2007, Volume 357, Issue 11, pp. 1105 - 1112
Journal Article
14.